Illumina CEO Jay Flatley said this week that the company has addressed previously reported backlog issues related to the company's Eco real-time PCR instrument.
"Demand for our Eco real-time PCR instrument is continuing to build nicely," Flatley said during a conference call discussing the company's Q1 earnings, released earlier this week. "We experienced some initial challenges in ramping manufacturing that we believe are now behind us. We're significantly scaling Eco production and expect to deliver the product with standard lead times by the end of this quarter."
Illumina launched the Eco last July following the acquisition of Helixis, which developed the platform's underlying technology. The sub-$15,000 system is aimed at researchers desiring a personal benchtop PCR instrument with performance comparable to more expensive systems often found in core labs (PCR Insider, 7/29/10).
In January, discussing Illumina's Q4 and full-year 2010 financial results, Flatley told investors that Q4 2010 orders for the Eco tripled from Q3, but that the company was experiencing "constraints" in its supply chain, and planned to move manufacturing of the product to its Singapore facility this year.
lllumina this week reported a 47 percent increase in Q1 2011 revenues, fueled by growth in its sequencing business and demand for its HiSeq 2000 systems.